DK3134530T3 - Behandling af hyperbilirubinæmi - Google Patents

Behandling af hyperbilirubinæmi Download PDF

Info

Publication number
DK3134530T3
DK3134530T3 DK15719677.5T DK15719677T DK3134530T3 DK 3134530 T3 DK3134530 T3 DK 3134530T3 DK 15719677 T DK15719677 T DK 15719677T DK 3134530 T3 DK3134530 T3 DK 3134530T3
Authority
DK
Denmark
Prior art keywords
rubiny
hyperbilir
treatment
hyperbilir rubiny
Prior art date
Application number
DK15719677.5T
Other languages
English (en)
Inventor
Federico Mingozzi
Giuseppe Ronzitti
Fanny Collaud
Andrés Muro
Giulia Bortolussi
Original Assignee
Genethon
Int Centre For Genetic Engineering And Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genethon, Int Centre For Genetic Engineering And Biotechnology filed Critical Genethon
Application granted granted Critical
Publication of DK3134530T3 publication Critical patent/DK3134530T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01017—Glucuronosyltransferase (2.4.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK15719677.5T 2014-04-25 2015-04-27 Behandling af hyperbilirubinæmi DK3134530T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14305622 2014-04-25
EP14196400 2014-12-04
PCT/EP2015/059099 WO2015162302A2 (en) 2014-04-25 2015-04-27 Treatment of hyperbilirubinemia

Publications (1)

Publication Number Publication Date
DK3134530T3 true DK3134530T3 (da) 2019-09-09

Family

ID=53039406

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15719677.5T DK3134530T3 (da) 2014-04-25 2015-04-27 Behandling af hyperbilirubinæmi
DK21151019.3T DK3851537T3 (da) 2014-04-25 2015-04-27 Behandling af hyperbilirubinæmi

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK21151019.3T DK3851537T3 (da) 2014-04-25 2015-04-27 Behandling af hyperbilirubinæmi

Country Status (10)

Country Link
US (3) US10471132B2 (da)
EP (3) EP3546585A1 (da)
JP (3) JP6730193B2 (da)
CN (2) CN106459932B (da)
AU (1) AU2015250770B2 (da)
CA (2) CA2942451A1 (da)
DK (2) DK3134530T3 (da)
ES (2) ES2744565T3 (da)
FI (1) FI3851537T3 (da)
WO (1) WO2015162302A2 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
EP3319631A4 (en) 2015-07-08 2019-01-09 American Gene Technologies International Inc. HIV PREMUNICATION AND IMMUNOTHERAPY
MA43415A (fr) * 2015-12-09 2018-10-17 Modernatx Inc Arnm modifié codant pour une uridine diphosphate glucuronosyltransférase et utilisations associées
WO2017106345A1 (en) * 2015-12-14 2017-06-22 The Trustees Of The University Of Pennsylvania Composition for treatment of crigler-najjar syndrome
JP7007273B2 (ja) 2015-12-22 2022-01-24 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 遺伝子治療用の改良された複合型二重組換えａａｖベクターシステム
IL310925A (en) 2016-01-15 2024-04-01 American Gene Tech Int Inc Methods and preparations for activating GAMMA-DELTA T cells
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖワクチン接種および免疫療法
EP4036231A1 (en) 2016-03-09 2022-08-03 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
CN105721252B (zh) * 2016-03-24 2020-09-25 腾讯科技（深圳）有限公司 数据包乱序度的测量方法和系统
GB201608046D0 (en) * 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
US11976292B2 (en) 2016-06-08 2024-05-07 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
CA3028982A1 (en) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
JP7176756B2 (ja) 2016-07-21 2022-11-22 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド パーキンソン病を処置するためのウイルスベクター
CN117384890A (zh) 2016-09-12 2024-01-12 吉尼松公司 酸性α-葡萄糖苷酶变体及其用途
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
CA3053455A1 (en) 2017-03-10 2018-09-13 Genethon Treatment of glycogen storage disease iii
CA3057142A1 (en) 2017-04-03 2018-10-11 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
US11596698B2 (en) * 2017-07-07 2023-03-07 Genethon Synthetic polynucleotides encoding a human FKRP protein
AU2018345745A1 (en) * 2017-10-02 2020-04-30 American Gene Technologies International Inc. Vectors with promoter and enhancer combinations for treating phenylketonuria
CA3086942A1 (en) 2018-02-07 2019-08-15 Genethon Hybrid regulatory elements
JP7142815B2 (ja) * 2018-06-21 2022-09-28 株式会社遺伝子治療研究所 ヒト肝臓への遺伝子導入のためのアデノ随伴ウイルスビリオン
CN109082402B (zh) * 2018-08-06 2021-08-17 复旦大学 一种aav-dj型腺相关病毒体外高效感染类器官的用途
BR112021002202A2 (pt) 2018-08-08 2021-05-04 Genethon mini-gde para o tratamento de doença de armazenamento de glicogênio iii
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
EP3864161A4 (en) * 2018-10-09 2022-11-23 The University of North Carolina at Chapel Hill REGULATED GENE EDIT SYSTEM
JP2022516010A (ja) * 2018-12-21 2022-02-24 ジェネトン 遺伝子療法ベクターのための発現カセット
IT201900008877A1 (it) * 2019-06-13 2020-12-13 Univ Bologna Alma Mater Studiorum Nuovi costrutti per terapia genica
CA3151442A1 (en) 2019-10-22 2021-04-29 Pasqualina COLELLA Sortilin receptor ligand based chimeric polypeptides and uses thereof
WO2021078834A1 (en) 2019-10-22 2021-04-29 Genethon Chimeric acid-alpha glucosidase polypeptides and uses thereof
EP3913060A1 (en) 2020-05-22 2021-11-24 Genethon Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
JP2023539219A (ja) 2020-08-24 2023-09-13 ジェネトン 糖原病ｉｉｉの治療のためのｃ末端切断ｇｄｅ
AU2021358957A1 (en) 2020-10-07 2023-06-08 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21
WO2022177597A1 (en) * 2021-02-16 2022-08-25 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods to enhance rna stability and translation and uses thereof
WO2023237731A1 (en) 2022-06-09 2023-12-14 Genethon N-terminal truncated gde for the treatment of glycogen storage disease iii

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05501054A (ja) * 1989-07-24 1993-03-04 セラジェン・インコーポレーテッド 内部翻訳開始の防止
US5910434A (en) * 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
CA2238434A1 (en) * 1995-12-15 1997-06-19 Systemix, Inc. Method for obtaining retroviral vector supernatant having high transduction efficiency
ATE323166T1 (de) * 2000-10-13 2006-04-15 Chiron Corp Fragmente der intron a von citomegalovirus
ES2932278T3 (es) 2004-06-01 2023-01-17 Genzyme Corp Composiciones y métodos para prevenir la agregación del vector AAV
US20100028312A1 (en) * 2005-03-24 2010-02-04 Caritas St. Elizabeth Medical Center of Boston Inc Stably transformed bone marrow-derived cells and uses thereof
JP2008539698A (ja) 2005-04-29 2008-11-20 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 転写後レベルでの核酸発現調節のための方法および組成物
US8129510B2 (en) * 2006-03-30 2012-03-06 The Board Of Trustees Of The Leland Stanford Junior University Minigene expression cassette
KR101229418B1 (ko) 2007-06-15 2013-02-05 재단법인 목암생명공학연구소 활성형 재조합 혈액응고 9인자의 대량생산 방법
EP2014301A1 (en) * 2007-07-13 2009-01-14 TopoTarget Germany AG Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
CN101348786B (zh) * 2007-07-20 2011-05-11 谭孟群 一种人β珠蛋白基因及其重组腺相关病毒载体
WO2010036118A1 (en) * 2008-09-29 2010-04-01 Amsterdam Molecular Therapeutics (Amt) B.V. Porphobilinogen deaminase gene therapy
CN101671740B (zh) * 2009-10-19 2012-05-23 广州益善生物技术有限公司 Ugt1a1基因多态性检测的方法及液相芯片
EP2496712A1 (en) * 2009-11-06 2012-09-12 Enzymatics Inc. Composition and method for synthesizing a deoxyribonucleotide chain using a double stranded nucleic acid complex with a thermostable polymerase
WO2011106759A1 (en) * 2010-02-26 2011-09-01 The Children's Hospital Of Philadelphia Protein c zymogen and methods of use thereof to prevent cancer metastases
DK2797613T3 (da) * 2011-10-27 2020-03-02 Wellstat Ophthalmics Corp Vektorer, der koder for rod-derived cone viability-faktor
CN102643906A (zh) * 2012-04-01 2012-08-22 周宏灏 焦磷酸测序法检测伊立替康个体化用药基因多态性的试剂盒及方法
CA2868391A1 (en) * 2012-04-02 2013-10-10 Stephane Bancel Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
JP6205359B2 (ja) * 2012-07-23 2017-09-27 有限会社生物資源研究所 ワクチン
CN103146804B (zh) * 2013-02-04 2015-04-22 中国科学院大连化学物理研究所 葡萄糖醛酸转移酶ugt1a1的特异性探针底物及应用
SG10201809075XA (en) 2013-07-22 2018-11-29 Childrens Hospital Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
CN104789532B (zh) * 2015-03-30 2019-06-11 汉恒生物科技（上海）有限公司 一种表达腺病毒的细胞株及高效制备腺病毒的方法

Also Published As

Publication number Publication date
EP3546585A1 (en) 2019-10-02
ES2744565T3 (es) 2020-02-25
CN114395559A (zh) 2022-04-26
WO2015162302A3 (en) 2015-12-30
JP2020103300A (ja) 2020-07-09
JP2022088645A (ja) 2022-06-14
FI3851537T3 (fi) 2024-03-21
EP3851537B1 (en) 2023-12-27
CA3205555A1 (en) 2015-10-29
JP7349931B2 (ja) 2023-09-25
JP2017513501A (ja) 2017-06-01
US10471132B2 (en) 2019-11-12
US20170028036A1 (en) 2017-02-02
US20230414724A1 (en) 2023-12-28
EP3134530A2 (en) 2017-03-01
AU2015250770A1 (en) 2016-09-29
AU2015250770B2 (en) 2020-10-01
JP6730193B2 (ja) 2020-07-29
CN106459932A (zh) 2017-02-22
DK3851537T3 (da) 2024-03-18
EP3851537A1 (en) 2021-07-21
CN106459932B (zh) 2022-01-11
US20190374619A1 (en) 2019-12-12
ES2971434T3 (es) 2024-06-05
WO2015162302A2 (en) 2015-10-29
EP3134530B1 (en) 2019-06-12
CA2942451A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
DK3134530T3 (da) Behandling af hyperbilirubinæmi
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3180331T3 (da) Polymorfer af selinexor
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK2968208T3 (da) Behandling af kataplexi
DK3461891T3 (da) Nedstrømsbehandling af en alkalisk phosphatase
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3231444T3 (da) Ny behandling
DK3307267T3 (da) Behandling af multipel sklerose
DK3283210T3 (da) Fremgangsmåde
DK3132009T3 (da) Fremgangsmåde
DK3237621T3 (da) Varianter af human alpha-galactosidase
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
DK3201323T3 (da) Modificering af bakteriofag
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK3151814T3 (da) Behandling af en hudlæsion
DK3143123T3 (da) Mikrorna-induktion af kardiologisk regenerering
DK3122349T3 (da) Sammensætninger til behandling af autodigestion
DK2897382T3 (da) Forbedring af binaural kilde
DK3418273T3 (da) Derivater af flavagliner
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier